文献速递甲状腺疾病

Bethesda III 甲状腺结节的分子检测:单中心实施趋势、细胞病理学判读率、手术率与恶性检出率

Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution.
PubMed 文献 · Thyroid · 2024-01-01

该单中心回顾性横断面研究分析了2017至2021年8960例细针穿刺(FNA),评估分子检测(MT)在社区与学术站点的采用趋势及其对Bethesda III(BIII)判读率、手术率和恶性检出率的影响。MT可及前后BIII率和MT使用率均显著增加(p<0.001),最终病理恶性检出率无显著变化(57.1% vs 50.0%,p=0.347),MT阳性预测值从85%降至50%(p=0.008,置信区间下降9.5-52.5%)。作者认为MT可及性增加可能无意中导致BIII病变、MT使用和良性结节手术率上升。

要点

  • MT可及前后BIII判读率和MT使用率均显著增加(p<0.001)。
  • 最终病理恶性检出率无显著变化(57.1% vs 50.0%,p=0.347)。
  • MT阳性预测值从85%降至50%(p=0.008,置信区间下降9.5-52.5%)。

核心结论

  • MT使用在研究期间全院增加,最大增幅出现在常规收集专用MT样本后。
  • MT可及性增加可能无意中导致BIII病变率、MT使用率和良性结节手术率上升。
  • 使用MT的医生应了解其采用的潜在后果以适当告知患者。

研究设计与样本

  • 回顾性横断面研究,纳入2017至2021年本机构分析的所有细针穿刺(FNA),共8960例。
  • 按平台和社区或学术站点分析MT使用趋势。
  • 采用卡方分析和线性回归比较MT可及前后BIII判读率、MT使用率、后续手术率和最终病理恶性检出率。

主要发现

  • MT在社区和学术站点均广泛采用。
  • MT可及前后BIII率显著增加(p<0.001),MT使用率显著增加(p<0.001)。
  • 最终病理恶性检出率无显著变化(57.1% vs 50.0%,p=0.347)。
  • MT阳性预测值从85%降至50%(p=0.008,置信区间9.5-52.5%下降)。

临床怎么用

  • 作者认为使用MT的医生应了解其采用的潜在后果以适当告知患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Molecular testing (MT) has become standard practice to more accurately rule out malignancy in indeterminate Bethesda III (BIII) thyroid lesions. We sought to assess the adoption of this technology and its impact on cytology reporting, malignancy yield, and rates of surgery across community and academic sites affiliated with a tertiary medical center. Methods: We performed a retrospective cross-sectional study including all fine-needle aspirations (FNAs) analyzed at our institution from 2017 to 2021. We analyzed trends in MT utilization by platform and by community or academic site. We compared BIII call rates, MT utilization rates, rates of subsequent surgery, and malignancy yield on final pathology before and after MT became readily available using chi-square analysis and linear regression. Results: A total of 8960 FNAs were analyzed at our institution from 2017 to 2021. There was broad adoption of MT across both community and academic sites. There was a significant increase in both the BIII rate and the utilization of MT between the pre- and post-MT periods (p < 0.001 and p < 0.001). There was no significant change in the the malignancy yield on final pathology (57.1% vs. 50.0%, p = 0.347), while the positive predictive value of MT decreased from 85% to 50% (p = 0.008 [confidence interval 9.5-52.5% decrease]). Conclusions: The use of MT increased across the institution over the study period, with the largest increase seen after a dedicated pass for MT was routinely collected. This increased availability of MT may have led to an unintended increase in the rates of BIII lesions, MT utilization, and surgery for benign nodules. Physicians who use MT should be aware of potential consequences of its adoption to appropriately counsel patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Stillman MD, Kuo EJ, Liou R, et al. Molecular Testing for Bethesda III Thyroid Nodules: Trends in Implementation, Cytopathology Call Rates, Surgery Rates, and Malignancy Yield at a Single Institution. Thyroid. 2024. PMID: 38468547. doi:10.1089/thy.2023.0664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。